Procanbid (procainamide hydrochloride extended-release tablets)
Company: Warner-LambertApproval Status: Approved January 1996
Treatment for: ventricular arrhythmias
Areas: Cardiovascular / Cardiology
| General Information | Additional Information |
General Information
Procanbid has been approved for the treatment of ventricular arrhythmias. While other procainamides are designed for dosage every six hours, patients taking Procanbid can achieve therapeutic blood levels with dosing every 12 hours.
Procanbid is available in 500 mg and 1000 mg tablets.
Additional Information
Ventricular arrhythmia often arises from atypical electrical activity in the ventricles that causes the heart to beat abnormally and affects approximately one million people annually in the United States. The condition is responsible for more than 80 percent of sudden cardiac deaths (SCD). In the United States, approximately 400,000 SCDs occur each year.
Procanbid Drug Information
The Procanbid drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.
